Relay Therapeutics Names Linda A. Hill, Ph.D., to Its Board of Directors
“Relay Therapeutics is committed to integrating talented people across disciplines to create new medicines for patients,” said Sarah O’Brien, chief people officer of Relay Therapeutics. “Linda’s research and real life understanding of building and sustaining a culture of innovation will be essential to us as we grow our organization over the coming years.”
Dr. Hill is the author of several leadership books and articles on leadership and innovation, including Collective Genius: The Art and Practice of Leading Innovation. Her research focuses on building innovative organizations and ecosystems and the role of the board in governing innovation. She is a member of the board of directors of Harvard Business Publishing and the Global Citizens Initiative, Inc. Dr. Hill serves on the board of trustees of the Art College of Design and serves on the advisory board of Eight, Inc., the Aspen Institute Business and Society Program, the California Institute for Telecommunications and Information Technology (Calit2), and the American Repertory Theater. Dr. Hill co-founded Paradox Strategies, a leadership research and advisory firm, and consults in the areas of leadership development, talent management, leading change and innovation, and managing cross-organizational relationships. Organizations with which Dr. Hill has worked include General Electric, IBM, MasterCard, Salesforce.com and The World Economic Forum. Dr. Hill holds a Ph.D. in behavioral sciences and a M.A. in educational psychology from the University of Chicago. She completed a postdoctoral research fellowship from Harvard Business School.
“I am thrilled to have the opportunity to work with the Relay Therapeutics team to progress its pipeline and build toward the goal of helping patients. I look forward to joining a team that has such a relentless focus on embedding a unique culture and values across the company,” said Dr. Hill.
About Relay Therapeutics
Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and by focusing on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 and has raised $120 million in financing to date from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital, Section 32, Alexandria Venture Investments, and an affiliate of D. E. Shaw Research.
Katie Engleman, +1 910-632-0405
Source: Relay Therapeutics